Concord Biotech Ltd
CONCORDBIOBSE 543960PharmaceuticalsMkt cap ₹14,385 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹257 Cr
YoY +26.2%QoQ -21.0%
Net profit · Q1 FY27
₹57.70 Cr
YoY +31.0%QoQ -34.8%
Net margin · Q1 FY27
22.4%
+0.8 pts vs Q1 FY26
Net profit · FY26
₹259 Cr
YoY -30.2%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 257 | 326 | 278 | 247 | 204 | +26.2% |
| Other income | 12.83 | 15.35 | 9.98 | 13.35 | 13.68 | -6.2% |
| Total income | 270 | 341 | 288 | 260 | 218 | +24.2% |
| Profit before tax | 77.07 | 114 | 86.85 | 83.39 | 57.24 | +34.6% |
| Tax | 20.65 | 25.61 | 22.51 | 22.62 | 14.67 | +40.8% |
| Net profit | 57.70 | 88.47 | 63.64 | 63.06 | 44.06 | +31.0% |
| Net margin | 22.4% | 27.1% | 22.9% | 25.5% | 21.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | YoY |
|---|---|---|---|---|
| Revenue | 1,055 | 1,200 | 1,017 | -12.1% |
| Other income | 52.36 | 44.45 | 33.78 | +17.8% |
| Total income | 1,107 | 1,245 | 1,051 | -11.0% |
| Profit before tax | 342 | 496 | 409 | -31.1% |
| Tax | 85.42 | 123 | 104 | -30.5% |
| Net profit | 259 | 372 | 308 | -30.2% |
| Net margin | 24.6% | 31.0% | 30.3% |
BIC's take
We haven't covered Concord Biotech Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:37 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.